Alnylam Pharmaceuticals: Promising Advancements in Alzheimer’s Treatment with RNA Interference Therapeutics
Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), boosting the price target to ...
J.P. Morgan Remains a Hold on Alnylam Pharma (ALNY)
In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Hold rating on Alnylam Pharma (ALNY – Research Report), with a price ...
BioPharma Dive1d
Sarepta rebuilds drug pipeline with Arrowhead deal
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...
BioPharma Dive1d
Kronos, Idorsia plan layoffs; PTC shelves ALS drug
Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC ...
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper Sandler 36th Annual Healthcare ...
BioSpace2d
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
pharmaphorum2d
NICE backs AZ/Ionis' Wainzua for ATTR polyneuropathy
New guidance from health technology assessment (HTA) agency NICE backs the use of Wainzua (eplontersen) to treat stage 1 or 2 ...
ETF Daily News2d
What is Zacks Research’s Estimate for ALNY FY2024 Earnings?
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Investment analysts at Zacks Research increased their FY2024 ...
Hosted on MSN2d
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
Hemophilia B Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Pipeline, Epidemiology and Companies by DelveInsight
DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding ...
Check Out What Whales Are Doing With ALNY
Delving into the details, we found 5% of traders were bullish, while 84% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $931,387, and 5 were calls, valued ...
BioSpace3d
Days After BridgeBio Approval, FDA Agrees to Review Alnylam’s Amvuttra in ATTR-CM
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...